Global /South Korea /Healthcare /Drug Manufacturers - General /196300

HLB Pep Co., Ltd.

196300

• KRX: 196300 • Delayed

7,150KRW -1.5%

4.68 USD

As of 13 June 2026, HLB Pep Co., Ltd. has a market cap of $44.3M USD, ranking #31439 globally and #1833 in South Korea. It ranks #2849 in the Healthcare sector, and #994 in the Drug Manufacturers - General industry.

Global Rank

31439

Country Rank

1833

Sector Rank

2849

Industry Rank

994

Key Stats

Market Cap

$44.3MUSD

67.38B KRW

Enterprise Value

$34.87MUSD

53.22B KRW

Revenue (TTM)

$3.26MUSD

4.96B KRW

EBITDA (TTM)

-$3.28MUSD

-5.01B KRW

Net Income (TTM)

-$422.45KUSD

-642.47M KRW

EBITDA Margin

-101%

Profit Margin

-13%

PS Ratio

13.6

PB Ratio

2.6

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jae Il Kim open_in_new

Founded

2000

Website

hlbpep.co.kr open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.5%	-1%	0.7%	-14%	7.1%	1.4%	-30%	-48%	-52%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	196300 애니젠(주) ISIN: KR7196300008 Shares Out.: Shares Outstanding: 9.376M¹ Shares Float: 8.494M² TV: TradingView: KRX: 196300 SA: Stock Analysis: KRX: 196300 YF: Yahoo Finance: 196300.KS GF: Google Finance: KRX: 196300 BA: Barron's: 196300 MS: Morningstar: XKRX: 196300	7,150 KRW	TV: TradingView: KRX: 196300 SA: Stock Analysis: KRX: 196300 YF: Yahoo Finance: 196300.KS GF: Google Finance: KRX: 196300 BA: Barron's: 196300 MS: Morningstar: XKRX: 196300

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About HLB Pep Co., Ltd.

HLB Pep Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It offers GMP, generic, custom, and catalog peptides, as well as offers other services. The company develops AGM-130, which is in Phase I for the treatment of triple negative breast cancer. In addition, its pre-clinical products include AGM-331 targeted for anti-cancer therapy; AGM-380 indicated for the treatment of viral infection; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria. In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes; AGM-217 indicated for the treatment of Type 2 diabetes and obesity; and AGM-260 indicated for the treatment of Ulcerative colitis. The company was formerly known as Anygen Co., Ltd. and changed its name to HLB Pep Co., Ltd. in April 2025. The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.15B 13.91T KRW 21K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.77B 10.3T KRW 15K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.24B 7.97T KRW 12K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.96B 7.55T KRW 11K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.55B 6.92T KRW 10K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.44B 6.76T KRW 10K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 814K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 726K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 652K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 620K%	20.5	Switzerland

chevron_leftBack